Daniel George, MD:This is a case of a 52-year-old gentleman who initially presented with some back pain in his left flank. In workup, a large left renal mass was found. He was also noted to have a couple of small lytic lesions in his lumbar spine. But, based upon this presentation, he is highly suspicious for renal cell carcinoma. He underwent a cytoreductive nephrectomy, which revealed grade 3 clear-cell carcinoma. Following his surgery, he recovered and was restaged.
At that time, the lytic lesions were shown to have grown and he had new lung nodules. So, the patient underwent radiation therapy to his lytic lesions in his lumbar spine, and then was immediately started on cabozantinib, 60 mg a day. He initially tolerated the 60-mg dose of cabozantinib quite well. However, after about 6 weeks on therapy, he started developing increased nausea, vomiting, and diarrhea. Based upon these symptoms, his dose was reduced to 40 mg a day. He tolerated this well. At 3 months’ time, he was restaged. At this point, his back pain was gone and his lung nodules had significantly decreased, suggesting a partial response to therapy.
Transcript edited for clarity.
Case Scenario: A 52-year old male with mRCC
February 2018
Tolerability Helps Decide Third-Line Treatment in Advanced RCC
April 30th 2024During a Case-Based Roundtable® Chandler H. Park, MD, led a discussion on the considerations physicians have when deciding on their treatment approach in the third line for patients with advanced renal cell carcinoma in the first article of a 2-part series.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Roundtable Roundup April: Renal Cell Carcinoma
April 27th 2024In separate, live virtual events, Arnab Basu, MD, MPH, and Robert J. Motzer, MD, asked participants which therapy they would choose for a patient with clear cell renal cell carcinoma (RCC) and why they would make that choice.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Ornstein Advises on Starting Dose and Management of Lenvatinib in RCC
April 21st 2024During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, provided guidance on dosing and toxicity concerns in a patient treated with lenvatinib plus pembrolizumab for advanced renal cell carcinoma.
Read More